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The human C3b/C4b receptor (CR1) is present on the surface of E, polymor- 
phonuclear  leukocytes, monocytes/macrophages,  B  lymphocytes, some T  lym- 
phocytes, follicular dendritic cells, and glomerular podocytes (1, 2). CR 1 mediates 
the binding to these cells of particles or immune complexes on which C3b has 
been deposited by complement activation (1).  ~90%  of the CR1  that is present 
in  blood  resides  on  E  (3),  and  this  CR1  is  considered  to  have  a  role  in  the 
clearance and processing of circulating immune complexes (4, 5). 
CR1  is  a  large  glycoprotein composed  of a  single polypeptide chain  that  is 
polymorphic with respect to molecular weight (6-9).  Three of the allotypes, S, 
F,  and  F',  have apparent  molecular weights in  the  reduced state  of 260,000, 
240,000,  and 210,000,  respectively, as determined by SDS-PAGE.  The molec- 
ular weight difference between the S and F allotypes is not abolished by removal 
of N-linked  oligosaccharides,  suggesting  that  the  polymorphism  is  caused  by 
differences in the length of the polypeptide chain (7). 
A  quantitative  polymorphism  of CR1  that  is  independent  of the  structural 
polymorphism has also been described (10).  The number of CR1  expressed by 
different cell types ranges from an average of 500 sites per cell for E to 40,000 
sites per cell for neutrophils, monocytes, and B iymphocytes (3,  10,  11).  Whereas 
the number of CR1  on leukocytes varies little between individuals (12),  E from 
different normal individuals may show up to  10-fold variation in their number 
of CR1  per  cell  (10).  The  possibility  that  these  differences  were  genetically 
determined was initially suggested by their persistence over time and by pedigree 
analyses of normal families (10).  This possibility is of particular importance, as 
studies  ill  two  populations have suggested that  inheritance plays a  role  in  the 
decreased numbers of CR 1 on E of patients with systemic lupus erythematosus 
(10,  13,  14).  A  mechanism for the genetic determination of CR1  number on E 
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was suggested by the observation that the frequency distribution  of this number 
in  the  normal  population  was  not  unimodal  (10,  14);  rather,  two  groups  of 
individuals  were  found  to  have numbers  of CR1  in  the  high  and  intermediate 
range  of the  population,  respectively,  with  a  third,  less  distinct  group  having 
numbers  in  the  lower  range.  It  was  proposed  that  this  distribution  reflected 
polymorphism of a regulatory element having at least two autosomal codominant 
alleles.  Additional  evidence for the  existence of such a  regulatory element  has 
now been  obtained  by the  identification  of a  CR1  genomic polymorphism that 
correlates with the level of CR1  expression on E. 
Materials and  Methods 
Antibodies.  Rabbit IgG anti-CR1 was prepared as described previously (3). The murine 
monoclonal IgG1 anti-CRl YZ-I (15) was purified from ascites by precipitation with 50% 
saturated ammonium sulfate and chromatography on  DEAE Sephacel (Pharmacia Fine 
Chemicals, Piscataway, N  J), and portions were radiolabeled with  ~z~I (Amersham Corp., 
Arlington  Heights,  IL) to sp act of 0.8-1.4  X  106  cpm/#g (16).  Fab fragments of the 
purified YZ-1  were produced by papain digestion (17) and were radiolabeled to asp act 
of 1.4 x  10 ~ cpm/ug. Murine IgG1 from the tumor line MOPC 21, which has no known 
antigen-binding activity (Litton Bionetics, Kensington, MD); biotin-conjugated monoclo- 
nal anti-B1 (Bl-biotin; ~  Coulter Electronics Inc., Hialeah, FL), which recognizes a 35,000 
M, antigen present on the surface of B lymphocytes (18), and FITC-conjugated goat IgG 
anti-mouse IgG (FITC-GaM) (Southern Biotechnology Associates, Birmingham, AL) were 
purchased. 
Enumeration  of CR1  of Erythrocytes,  Neutrophils,  and  B  Lymphocytes.  The number of 
CR1  on erythrocytes was determined by incubation  of washed erythrocytes for  1 h  at 
22°C with 1 ~g/m1125I-YZ-I in the absence or presence of excess, unlabeled YZ-1 followed 
by  centrifugation  of the  erythrocytes  through  cushions  of dibutylphthalate  (Eastman 
Kodak Co.,  Rochester,  NY)  (10).  Total  cellular CR1  of purified  neutrophils  (19)  was 
measured by a modification of the sandwich protocol of Unkeless and Healy (20,  21) in 
which  the  detergent-soluble fraction of lysates of neutrophils  was incubated  with  1.25 
tlg/ml  J25I-YZ-1  Fab,  and  the  CR1J2~I-Fab  complexes  were  immunoprecipitated  by 
Staphylococcus  aureus  particles  (Bethesda  Research  Laboratories,  Gaithersburg,  MD) 
charged with polyclonal rabbit lgG anti-CR1. CRI  on B lymphocytes was quantified by 
two-color immunofluorescent flow cytometry (12); B ceils were identified by staining with 
Bl-biotin  and  rbodamine  600  (XRITC)-conjugated avidin  (Vector  Laboratories,  Inc., 
Burlingame, CA), and the amount of CR 1 on the cells was measured by staining with YZ- 
1 and FITC-GaM. Immunofluorescent staining was analyzed with a Cytofluorograf System 
50-H  (Ortho  Diagnostic  Systems  Inc.,  Westwood,  MA)  ec]uipped  with  an  argon  laser 
operated at 488  nm and  250  mW and a  krypton laser operated at 568.2  nm and  200 
roW, and interfaced with a model 2150 Data Handler (Ortho Diagnostic Systems Inc.). 
Analysis of CR1 by PAGE.  CRI in detergent lysates oferythrocytes or neutrophils that 
had been surface-labeled with ~2.~! (16) was immunoprecipitated as described (7) using YZ- 
1  IgG that  had  been  coupled  to  CNBr-activated-Sepharose  (Sigma  Chemical  Co.,  St. 
Louis, M O). The immunoprecipitated CR 1 was eluted by incubation for 3 min at 100°C 
in  1% SDS and was analyzed after reduction  and alkylation by SDS-PAGE (22)  on slab 
gels containing a gradient of 3-10% acrylamide, followed by autoradiography. 
Southern  Blot Analysis  of Genomic DNA.  Genomic DNA was isolated from peripheral 
blood leukocytes (23) and analyzed by Southern blot hybridization (24) using the 0.75-kb 
CRI cDNA probe, CRI-I, which represents a portion ofa 1.2-kb sequence that occurs in 
at least two highly homologous copies in the coding sequence of the CR 1 gene (25, 26). 
Abbreviations used in this paper:  Bl-biotin,  biotin-conjugated monoclonal anti B-I; FITC-GaM, 
FITC-conjugated  goat  lgG  anti-mouse  IgG;  RFLP,  restriction  fragment length  polymorphism; 
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FIGURE  1.  Comparison of Hind III  RFLP with number of CR1  expressed on E. Genomic 
DNA from normal individuals was digested with Hind Ill, Southern blots of the DNA were 
probed with 32p-CRI-I, and hybridizing fragments were detected by autoradiography. Num- 
bers of CR 1/E are shown above the lanes and kb sizes of DNA fragments are indicated to the 
right and left of the autoradiogram. 
Results 
Leukocyte DNA  was prepared  from  healthy  individuals  having  numbers  of 
CR1  on their  E in the high  (708-1,114  CR1  sites per cell), intermediate  (478- 
570  sites  per  cell),  and  low  (174-208  sites  per  cell)  ranges,  respectively.  The 
DNA was digested with a panel of restriction  enzymes and Southern  blots were 
hybridized  with  the  0.75-kb  CR1  cDNA probe,  CRI-1.  This  probe hybridizes 
under"  stringent  conditions  not only to its complementary  sequence but also to 
other highly homologous sequences that occur within the coding sequence of the 
CR 1 gene (25, 26). The existence of these repeating sequences accounts, at least 
in  part,  for  the  multiple  genomic  restriction  fragments  to  which  the  probe 
hybridizes.  Using Hind III, we observed a restriction  fragment length polymor- 
phism (RFLP) involving fragments of 7.4 kb and 6.9 kb that appeared to correlate 
with  the  variations  in  the  quantitative  expression  of  CR1  (Fig.  1).  All  four 
individuals having high  CR 1 sites/E had only the 7.4-kb fragment,  three of the 
four persons having  low CR1  had  only the  6.9-kb  fragment,  and  three  of the 
four  individuals  having  intermediate  numbers  of  CRI  had  both  fi-agments. 
Therefore, a  larger" group of normal  individuals was analyzed for CR 1 number WILSON  ET  AL.  53 
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FIGURE  2.  CR1/E among normal  individuals grouped according to Hind  III  RFLP.  Each 
point represents data  for a  single individual. CRI/E are shown in  the vertical axis, and  the 
pattern for the Hind III  RFLP is shown diagramatically below each group. Points with error 
bars to the left of each group represent mean -+ SEM, and the p  values obtained when groups 
were compared in a two-sample t test are shown. 
on  E  and  for  the  occurrence  of these  Hind  III  restriction  fragments.  All  50 
individuals had  either  the 6.9-kb fragment,  the  7.4-kb fragment,  or both (Fig. 
2). The number of CR1 sites on E from persons having only the 7.4-kb restriction 
fragment was 611 +  33 (mean + SEM). Although there was considerable overlap, 
the  11 donors having both restriction fragments had significantly fewer sites per 
E,  455  +  52 (p <  0.005).  Individuals having only the 6.9-kb fragment showed 
less variation in CR1 expression than did the other two groups, not overlapping 
with any person  hontozygous for the 7.4-kb fragment,  and  had a  mean of only 
156 +  13  sites per E (significance of the difference of means for either  higher 
group, p <  0.001). 
The probe with which the Hind III RFLP was detected, CRI-1, shows in situ 
hybridization  to  a  single  chromosomal  locus,  lq32  (26).  The  linkage  of this 
RFLP  to  the  structural  gene  for  CR1  was  confirmed  by  examining  in  an 
informative family whether the Hind III restriction fragments cosegregated with 
the S,  F, and  F'  structural  allotypes of CR1  (Fig.  3A). In individuals  II-1,  II-2, 
III-l, and  III-2, gels of 125I-labeled  CR1  from both E (Fig.  3A) and neutrophils 
(Fig.  3B) were obtained  to aid  in  the  definitive assignment  of CR1  structural 
allotypes.  The  individual  designated  I-2  was  heterozygous  for  the  F  and  F' 
structural  allotypes and  homozygous for the  7.4-kb  Hind  III  fragment.  Every 
descendant of I-2 who inherited the F' allotype (II-1, II-2, III-1, and III-2) also 
had the 7.4-kb Hind II!  fragment.  The  F allotype of individual  II-1  was neces- 
sarily  inherited  from  his  father,  individual  I-I,  and  this  allotype cosegregated 
with the  6.9-kb Hind  III  fragment  in  all  cases, including  individuals  II-1,  II-2, 
and III-3.  Finally, the S and F allotypes of individual II-3 cosegregated with the 
7.4- and 6.9-kb Hind III fragments,  respectively, in individuals III-1, III-2, and 
III-3.  Thus,  the  element  identified  by the  Hind  III  RFLP  that  regulates  the 
quantitative expression of CR1  is linked to the CR1 gene. 
Previous  studies  have  indicated  that  the  relative  proportions  of the  CR1 
structural  allotypes expressed on  E of different  heterozygous individuals  were 
relatively constant over time (6,  7),  and  have suggested that  these ratios might 
be genetically controlled (8, 9, Rodriguez de Cordoba, personal communication, 
New York  Blood Center,  New York).  Having shown  that  the  Hind  III  RFLP 54  GENETIC  REGULATION  OF  CR1  EXPRESSION  ON  ERYTHROCYTES 
FmURE 3.  Segregation in a normal family of Hind 111 RFLP, structural allotype of CR1 and 
C R 1/E.  N umber of CR 1/E is shown inside each symbol. An autoradiogram of the SDS-PAGE 
of CR1  protein immunoprecipitated from  each  individual's surface-l~51-1abeled E  is shown 
beneath each figure, and the positions of the S, F, and F' allotypes of CR1  and the 200-kD 
molecular mass marker are indicated. The 7.4-kb and 6.9-kb Hind III fragments that were 
seen in Southern blots of each individual's DNA are shown adjacent to the allotypic form of 
CR 1 with which they cosegregated. An autoradiogram of the SDS-PAGE of CR 1 immunopre- 
cipitated from surface-  l-labeled neutrophils of individuals II-1, II-2, III-1, and 111-2 is shown 
in the inset. 
and the locus defining the CR 1 structural allotypes are linked, it was possible to 
assess whether the regulatory element associated with this RFLP was cis- or trans- 
acting by comparing  the relative amounts  of the S, F, and F' allotypes expressed 
on  E  of the individuals depicted in  Fig.  3.  The  F' allotype that is associated with 
the  7.4-kb  Hind  III  fragment  in  individuals  I-2,  II-1,  II-2,  III-1,  and  III-2  is 
expressed in  large quantities  on  E  of each  of these  individuals.  In  contrast,  the 
6.9-kb  fragment-associated  F  allotype of individuals I-l,  II-1,  II-2, and  III-3  is 
expressed  in  relatively  small  quantities.  Thus,  the  regulatory  element  that  is WILSON  ET  AL.  55 
linked  to  these  7.4-kb and  6.9-kb  Hind  III  restriction  fragments  cis-regulates 
CR1  expression  by E.  The  expression  of the  S allotype of individual  II-3  that 
was  associated  with  the  7.4-kb  fragment  did  not  exceed  that  of his  6.9-kb 
fragment-associated F allotype. Moreover, the expression of this S allotype on E 
of individuals III-1 and III-3 was relatively low, and the three individuals having 
this allele had only 202, 326, and  192 CR1 sites per E, respectively. Therefore, 
in these individuals the factors causing low CR 1 number in association with the 
7.4-kb allele also were inherited and were expressed in a cis-acting manner. 
Visual  comparison  of  the  proportions  of  the  structural  allotypes  of  CR1 
expressed on E (Fig.  3A) and neutrophils (Fig.  3B) of individuals II-1, II-2,  III- 
1, and  III-2 of Fig.  3 suggested that  factors regulating the amounts of CR1  on 
these two cell  types may differ,  in  accord with  earlier  findings  (7,  9,  27).  To 
investigate  further  whether  such  regulation  might  be  cell-type-specific,  eight 
normal  individuals  were  selected,  four  homozygous  for  the  7.4-kb  Hind  III 
fragment and four homozygous for the 6.9-kb fragment, and CR1 was quantified 
on their E by the binding of 125I-YZ-1, on their B cells by two-color immunoflu- 
orescent flow cytometry, and  in  their  neutrophils  by a  sandwich  RIA of total 
cellular  CR1  (Fig.  4).  For B cells and neutrophils,  determinations  for all  eight 
individuals  were  performed  simultaneously  to  avoid  interassay  variation.  The 
mean number of CR1/E for the individuals homozygous for the 7.4-kb Hind III 
fragment  was  886  -+  94,  significantly  higher  than  that  for  the  individuals 
homozygous for the 6.9-kb fragment,  159 _+  18 (p <  0.001). When the amount 
of CR1  present  on  B  cells,  identified  by their  red  fluorescent staining  by B1- 
biotin  and  XRITC-avidin,  was  expressed  as  the  relative  intensity  of  green 
fluorescent staining by YZ-1  and FITC-GaM, B cells of the individuals who were 
homozygous for the 7.4-kb fragment had a  mean relative fluorescence for CR 1 
of 26.7 +  2 (SEM), not significantly different from that of B cells from individuals 
who were homozygous for the 6.9-kb fragment,  29.1 _+ 6 (p  >  0.2). The individ- 
uals homozygous for the 7.4-kb fragment and those homozygous for the 6.9-kb 
fragment  also  were  similar  in  the  total  amount  of CR1  in  their  neutrophils, 
43,870  +  4,010  and  42,985  +_  2,184  CR1/cell,  respectively (p  >  0.8).  Thus, 
regulation  of total CR1  expression by the element associated with the Hind III 
RFLP is apparent only in erythrocytes. 
Discussion 
In Southern blots of genomic DNA that had been digested with Hind III, the 
0.75-kb  probe,  CRI-1,  hybridized  to  multiple  fragments  having  an  aggregate 
length of ~80 kb (Fig.  1). This circumstance permitted analysis of a large portion 
of the CR 1 gene with a probe that was derived from < 10% of the CR 1 transcript 
(25). Among 50 healthy donors (Fig. 2), a polymorphism involving two restriction 
fragments of 6.9  kb and  7.4  kb was found to correlate  with  the  level of CR1 
expression on E. The occurrence in all individuals of either or both restriction 
fragments is consistent with their being allelic, and family studies supported this 
possibility (Fig.  3).  The additional  finding that  a  corresponding  polymorphism 
was not observed with the enzymes Eco RI, Bam HI, and Pvu II (data not shown) 
suggests either that the two alleles differ at only a few nucleotides or that there 
are cleavage sites for these three enzymes between the polymorphic region and 
the hybridization site for CR 1-1. 56  GENETIC  REGULATION  OF  CRI  EXPRESSION ON  ERYTHROCYTES 
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FIGURE 4.  Quantitation of CRI of E, neutrophils, and B lymphocytes of individuals homo- 
zygous for either the 7.4-kb or the 6.9-kb Hind III RFLP. Each point represents data for a 
single individual. Open circles with error bars to the left of each group represent mean --- 
SEM. 
Presumed homozygosity for the form of the regulatory element identified by 
the  6.9-kb and  by the  7.4-kb restriction  fragment was associated with  low and 
high numbers of CR 1 on E, respectively, whereas heterozygosity was associated 
with  CR1  number  on  E  in  the  intermediate  range  (Fig.  2).  This  regulatory 
element  was  shown  to  be  linked  to  the  CR1  structural  gene and cis-acting  by 
showing  that  it  regulated  the  relative amounts  of the  S,  F,  and  F'  structural 
allotypes of CR 1 expressed on E in three generations of a family (Fig. 3). Studies 
of CR1  expression  by  ]eukocytes suggested  that  the  effects of this  regulatory 
element were tissue-specific (Figs.  3 and 4). However, unequal expression of the 
CR 1 structural allotypes that paralleled that on E was also observed on neutro- 
phils of individual  III-2 of Fig.  3. 
Inherited differences in  the expression  of CR1  could  result  from  structural 
alterations affecting its membrane insertion or stability.  For example, inherited 
changes in the transmembrane and cytoplasmic domains of low density lipopro- 
tein receptors resulted in the secretion of most of these receptors from fibroblasts WILSON  ET  AL.  57 
(28).  Although  CR1  of E  from  individuals  homozygous  for  either  of the  two 
forms of the  Hind  III  RFLP did  not  differ on  SDS-PAGE and  there  was no 
corresponding alteration in CR 1 expression by their leuokocytes, possible differ- 
ences in protein structure of their CR1  can be excluded only by comparing the 
coding  sequences  of  the  CR1  genes  associated  with  the  6.9-kb  and  7.4-kb 
restriction  fragments.  Altered  stability  of CR1  resulting  from  differences  in 
primary structure of the receptor might be more apparent on erythrocytes than 
leukocytes because of the longer life span of the former cell type and its lack of 
biosynthetic capacity. 
Observed  differences  in  CR1  expression  also  could  be  caused  by  factors 
affecting protein  synthesis,  including  differential  transcription  initiation,  RNA 
splicing,  polyadenylation, rates of mRNA processing and transport,  stability of 
the message in the cytoplasm, or rates of translation or intracellular degradation. 
In  eukaryotic genes  the  steady state  levels of message appear  to  be regulated 
primarily  by modulation  of transcription  initiation  (29), as has been  found for 
the genes encoding Ig light and heavy chains (30-33),  insulin (34), and chymo- 
trypsin  (34).  Thus,  the  Hind  lII  RFLP  might  identify  allelic  forms  of either 
promoter  or  enhancer  elements,  both  of which  are cis-acting,  and  the  tissue- 
specific nature of the CR1 regulatory element may favor the possibility that it is 
an enhancer.  The  threefold span of CR1  number on E of individuals  who are 
homozygous for the  7.4-kb Hind III  fragment  indicates either  that a  recombi- 
nation  event  has  occurred  between  the  regulatory  element  and  the  Hind  III 
restriction  sites, or that  additional  genetic  factors influencing  CR1  expression 
are superimposed on the regulatory element identified in this study.  However, 
the  regulatory  element  associated  with  the  6.9-kb  Hind  III  fragment,  when 
present in the homozygous state, overrides the effects of such additional genetic 
factors (Fig. 2). 
Summary 
A  genetic  basis  for the  regulation  of the  number  of CR1  on  E  of different 
normal individuals was investigated by probing Southern blots of their genomic 
DNA with a  0.75-kb  fragment  of CR1  cDNA.  Using Hind III,  we observed a 
RFLP involving fragments of 7.4 kb and 6.9 kb that correlated with the number 
of CR1  on  E.  32  individuals baying only the  7.4-kb restriction  fragment had a 
mean of 661  +  33 (SEM) CR1/E,  11  donors having both restriction  fragments 
had  a  mean  of 455  +  52  CR1/E,  and  7  individuals  having  only  the  6.9-kb 
fi'agment had a mean of 1.56 +  13 CR1/E, all means being significantly different 
(p  <  0.005).  Cosegregation  in  a  normal  family  of the  Hind  III  restriction 
fragments with the S,  F, and  F'  structural  allotypes of CR1  confirmed that the 
regulatory  element  identified  by these  fragments  is  linked  to  the  CR1  gene. 
Moreover, an analysis of the relative expression on E of these structural allotypes 
in association with either the 7.4-kb Hind III fragment or the 6.9-kb fragment 
showed  that  this  regulatory  element  is cis-acting.  In  contrast,  quantitation  of 
CR1  of B  lymphocytes and  neutrophils  revealed  no  differences  in  total  CR1 
expression between individuals homozygous for the 7.4-kb and 6.9-kb Hind III 
fragments.  Thus,  we have identified a  genomic polymorphism that  is linked  to 58  GENETIC  REGULATION OF  CR1  EXPRESSION  ON  ERYTHROCYTES 
the  CR1  gene  and  is  associated  with  a  cis-acting  regulatory  element  for  the 
expression of CR1  on E. 
Received for publication  6 March  I986. 
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